Pear Therapeutics, Inc. (PEAR): Price and Financial Metrics
GET POWR RATINGS... FREE!
PEAR POWR Grades
- PEAR scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.23% of US stocks.
- The strongest trend for PEAR is in Growth, which has been heading down over the past 177 days.
- PEAR ranks lowest in Growth; there it ranks in the 6th percentile.
PEAR Stock Summary
- PEAR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.54 -- higher than only 4.96% of US-listed equities with positive expected earnings growth.
- With a price/sales ratio of 23.89, PEAR THERAPEUTICS INC has a higher such ratio than 94.64% of stocks in our set.
- Revenue growth over the past 12 months for PEAR THERAPEUTICS INC comes in at 172.08%, a number that bests 95.06% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to PEAR THERAPEUTICS INC, a group of peers worth examining would be DZSI, IBIO, SCWX, ALKS, and SQL.
- To dig deeper into the stock's financial statements, go to PEAR's page on browse-edgar?action=getcompany&CIK=0001835567.
PEAR Valuation Summary
- In comparison to the median Technology stock, PEAR's price/sales ratio is 838.46% higher, now standing at 24.4.
- Over the past 22 months, PEAR's price/sales ratio has gone down 3.2.
Below are key valuation metrics over time for PEAR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PEAR | 2022-12-02 | 24.4 | 5.3 | -9.2 | -9.4 |
| PEAR | 2022-12-01 | 23.3 | 5.1 | -8.8 | -9.0 |
| PEAR | 2022-11-30 | 22.6 | 4.9 | -8.5 | -8.7 |
| PEAR | 2022-11-29 | 21.6 | 4.7 | -8.1 | -8.3 |
| PEAR | 2022-11-28 | 21.3 | 4.7 | -8.0 | -8.1 |
| PEAR | 2022-11-25 | 24.5 | 5.4 | -9.2 | -9.5 |
PEAR Stock Price Chart Interactive Chart >
PEAR Price/Volume Stats
| Current price | $1.96 | 52-week high | $14.60 |
| Prev. close | $2.00 | 52-week low | $1.34 |
| Day low | $1.95 | Volume | 149,700 |
| Day high | $2.09 | Avg. volume | 336,396 |
| 50-day MA | $2.27 | Dividend yield | N/A |
| 200-day MA | $2.92 | Market Cap | 273.50M |
Pear Therapeutics, Inc. (PEAR) Company Bio
Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.
Latest PEAR News From Around the Web
Below are the latest news stories about PEAR THERAPEUTICS INC that investors may wish to consider to help them evaluate PEAR as an investment opportunity.
Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx ConferenceBOSTON, November 21, 2022--Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference |
''The mood around here today is not great'': Pear Therapeutics trims workforce by another 22%''The mood around here today is not great'': Pear Therapeutics trims workforce by another 22% apark Wed, 11/16/2022 - 09:50 |
Analysts Offer Insights on Healthcare Companies: Star Equity Holdings (STRR), Sutro Biopharma (STRO) and Pear Therapeutics (PEAR)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Star Equity Holdings (STRR – Research Report), Sutro Biopharma (STRO – Research Report) and Pear Therapeutics (PEAR – Research Report) with bullish sentiments. Star Equity Holdings (STRR) Maxim Group analyst Tate Sullivan reiterated a Buy rating on Star Equity Holdings yesterday and set a price target of $2.25. The company's shares closed last Monday at $0.90, close to its 52-week low of $0.72. According to TipRanks. |
Pear Therapeutics undergoes another round of layoffs, cutting 22% of staffThe digital therapeutics company said the reductions will extend its cash runway and curb its reliance on financing. |
Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call TranscriptPear Therapeutics Inc. (NASDAQ:NASDAQ:PEAR) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Director-Corporate Communications Corey… |
PEAR Price Returns
| 1-mo | -24.32% |
| 3-mo | 2.62% |
| 6-mo | -28.47% |
| 1-year | -80.40% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.39% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...